Universe Pharmaceuticals Inc.
Universe Pharmaceuticals Inc. (UPC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
upc · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Universe Pharmaceuticals Inc. (UPC) measures how much investors pay for each dollar of the company's trailing earnings. UPC's current PE ratio of N/A is calculated by dividing its stock price of $3.62 by its TTM earnings per share of -$6.52.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%13.2x
MedianQ3 · 75%13.2x
Max
At N/A, UPC's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Universe Pharmaceuticals Inc.You UPC | $2M | N/A | — | -$6.52 |
 BriaCell Therapeutics Corp. Warrant BCTXZ | $0M | N/A | — | -$62.95 |
 Bluejay Diagnostics, Inc. BJDX | $2M | N/A | — | -$15.25 |
 PMGC Holdings Inc. ELAB | $3M | N/A | — | -$378.74 |
 Moolec Science S.A. MLEC | $5M | N/A | — | -$258.69 |
 NewcelX Ltd. NCEL | $1M | N/A | — | -$26.31 |
 NKGen Biotech, Inc. Common Stock NKGN | $8M | N/A | — | -$1.54 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-1055.79 | — | |
2024-09-30 FY2024 | — | $-1436.12 | — | |
2023-09-30 FY2023 | — | $-1040.53 | — | |
2022-09-30 FY2022 | — | $-1475.02 | — | |
2021-09-30 FY2021 | 4.14x | $2147.18 | -68.6% | |
2020-09-30 FY2020 | 13.20x | $1295.77 | -0.1% | |
2019-09-30 FY2019 | 13.21x | $1294.61 | +0.7% | |
2018-09-30 FY2018 | 13.12x | $1303.43 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Universe Pharmaceuticals Inc. (UPC) measures how much investors pay for each dollar of the company's trailing earnings. UPC's current PE ratio of N/A is calculated by dividing its stock price of $3.62 by its TTM earnings per share of -$6.52.
Frequently asked questions
UPC pe ratio · 6 questionsUPC's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.62 and TTM EPS of -$6.52. Data sourced from Financial Modeling Prep via UPC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Universe Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09